Methotrexate in Crohn’s disease

D S Rampton

A minority of patients with Crohn’s have disease refractory to or dependent on corticosteroids who are inappropriate for surgery; most will also have failed to respond to aminosalicylates, antibiotics, and/or a liquid formula diet. Firstline immunomodulatory therapy, given to initiate and maintain remission and allow tapering of steroid therapy, is usually azathioprine or 6-mercaptopurine. Unfortunately, approximately 20% of patients are resistant to or intolerant of thiopurines, and their management provides a difficult therapeutic challenge. The possible benefits of mycophenolate mofetil are unconfirmed, while infliximab is expensive and unproved in its long term efficacy and safety.

Methotrexate is of proven value in psoriasis and rheumatoid arthritis. Since its effects in Crohn’s disease were first reported in an open trial 12 years ago, several uncontrolled and five controlled studies have further defined its role.

Mechanism of action
Methotrexate and its breakdown products inhibit several enzymes in the metabolic pathway of folic acid. While the cytotoxic and antiproliferative effects of high dose methotrexate are ascribed to inhibition of dihydrofolate reductase, with consequent inhibition of DNA, RNA, and protein synthesis, the anti-inflammatory and immunomodulatory actions of low doses are probably due to inhibition of other folate dependent enzymes. Long term low dose methotrexate may lead to accumulation of adenosine, a lymphotoxic, immunosuppressive, and anti-inflammatory cytokoid. Other effects include interleukin 1 (IL-1) receptor blockade, increased production of the regulatory cytokine IL-2, decreased production of soluble IL-2 receptors, IL-6, IL-8, leucotriene B4, and antibodies, and impairment of neutrophil chemotaxis.

Efficacy
The reported controlled trials differ in patient selection and numbers, dose, route and duration of methotrexate therapy, concurrent treatment, and outcome measures.

The two largest studies compared methotrexate with placebo in the induction and maintenance of remission. In the first study, of 94 patients with steroid resistant or steroid dependent Crohn’s disease given methotrexate 25 mg/week intramuscularly with tapering of oral prednisolone for 16 weeks, 39% entered remission compared with 19% given placebo (p=0.025, relative risk 1.95 (95% confidence intervals (CI) 1.09–3.48)). Subsequently, methotrexate 15 mg/week intramuscularly for 40 weeks maintained remission in 65% of 40 patients compared with 39% of patients given placebo (p=0.04, reduction in risk of relapse 26%, 95% CI 4–48%); use of prednisolone was halved.

The other published controlled trials are much smaller. In a dose-response study, only 17% of 32 patients given 15 or 25 mg/week subcutaneous methotrexate achieved remission by 16 weeks while 12.5 mg/week given orally was no more effective than placebo in either inducing (26 patients) or maintaining (10 patients) remission. Lastly, 15–22.5 mg/week methotrexate given orally in three divided doses for up to one year maintained remission in 54% of 13 patients given methotrexate compared with 20% of patients who received placebo (p=0.06).

Side effects
The potential benefits of methotrexate must be weighed against its side effects. Rash, nausea, diarrhoea, stomatitis, and other gastrointestinal symptoms necessitate its discontinuation in approximately 5% of patients. There are case reports of severe colitis complicating the use of methotrexate, although not yet in patients with Crohn’s disease. There is an increased risk of opportunistic infections, including herpes zoster and pneumocystis carinii pneumonia, but not of neoplasia other than lymphoproliferative disorders. The latter are related to previous infection with Epstein-Barr virus, and are sometimes reversible on methotrexate withdrawal. Because methotrexate is teratogenic, pregnancy or conception within six months of stopping treatment with methotrexate of either partner should be avoided. Breast feeding is also contraindicated.

Bone marrow depression occurs in up to 20% of patients with rheumatoid arthritis receiving low dose methotrexate but is usually reversible on stopping the drug or reducing the dose. Blood counts weekly initially and then every two months are mandatory. Risk factors include coadministration of other antifolate agents such as trimethoprim-sulphamethoxazole, and non-steroidal anti-inflammatory agents, penicillins, old age, and renal impairment, all of which reduce excretion of methotrexate. Concurrent long term folic acid reduces the incidence of cytopenias, stomatitis, and other digestive symptoms, without compromising the efficacy of methotrexate.

The risk of methotrexate induced hepatic fibrosis is higher in psoriasis than rheumatoid arthritis; limited data suggest that hepatotoxicity may be rare in Crohn’s disease. However, it is prudent to exclude from

Academic Department of Adult and Paediatric Gastroenterology, St Bartholomew’s and the Royal London School of Medicine and Dentistry; Turner St, London E1 2AD, UK

Correspondence to: Dr D S Rampton, Department of Gastroenterology, Royal London Hospital, London E11BB, UK, drampton@mds.qmw.ac.uk
Treatment patients who drink >7 units of alcohol/week, weigh >40% normal, or have diabetes. Serum transaminases and albumin should be checked every 1–2 months, and liver biopsy undertaken in patients with persistently abnormal values; biopsy should also be considered after a cumulative dose of 1.5 g. Hypersensitivity pneumonitis occurs in up to 10% of rheumatoid patients given methotrexate. Cough or dyspnoea should prompt chest x-ray, blood gases, and lung function tests, particularly carbon monoxide diffusing capacity.

Conclusions
Although North American trials suggest that methotrexate may have a valuable role in selected patients with steroid refractory or steroid dependent Crohn’s disease, there are unanswered questions. The minimum effective dose is unclear, available data indicating 25 mg weekly intramuscularly to induce and 15 mg weekly intramuscularly to maintain remission. Oral administration of methotrexate seems to increase the incidence of gastrointestinal side effects, particularly within 24 hours of dosing, but would be more convenient than injections if proven efficacious. While absorption of low dose oral methotrexate in Crohn’s disease, even in patients with severe small bowel disease or resections, appears satisfactory, a trial of enteral versus parenteral administration would be helpful. Exactly when to use methotrexate is uncertain. In steroid resistant or steroid dependent patients, should we use first a thiopurine, methotrexate, or mycophenolate? We also need to know whether, as in rheumatoid arthritis, methotrexate is more effective in combination with other therapies, such as infliximab. There is a clear requirement for further trials to clarify how best to use methotrexate in Crohn’s disease.